Opko Health (OPK) AI Stock Analysis

• Market Cap: $1.07B
• Dividend Yield: N/A
• Average Volume (3M): 2.18M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: -9.75%
• EPS Growth: -31.28%
• Country: US
• Employees: 2,997
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.03
• Shares Outstanding: 767,701,300
• 10 Day Avg. Volume: 1,466,492
• 30 Day Avg. Volume: 2,176,778
• PEG Ratio: 0.28
• Price to Book (P/B): 0.75
• Price to Sales (P/S): 1.43
• P/FCF Ratio: -4.89
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $2.75
• Price Target Upside: 79.74% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $1.50 ▼(-1.96% Downside)

Opko Health's overall stock score is primarily impacted by its challenging financial performance and valuation concerns. While strategic initiatives and partnerships provide some optimism, the company's financial difficulties and bearish technical indicators weigh heavily on the score.

Positive Factors

Strategic Partnerships

The collaboration with Regeneron to develop multispecific antibodies enhances Opko's R&D capabilities and could lead to innovative treatments, strengthening its competitive position in the biopharmaceutical industry.

Pipeline Advancements

Advancements in the pharmaceutical pipeline, including clinical trials, indicate potential future revenue streams and demonstrate Opko's commitment to innovation and long-term growth.

FDA Approval

FDA approval for the 4Kscore test without digital rectal examination expands its marketability, potentially increasing diagnostic segment revenues and strengthening Opko's market position.

Negative Factors

Revenue Decline

A decline in revenue indicates challenges in maintaining market share and operational efficiency, which could affect long-term financial stability and growth prospects.

Negative Profitability

Sustained negative profitability, exacerbated by significant expenses, highlights financial instability and could limit Opko's ability to invest in growth opportunities.

Cash Flow Issues

Negative operating cash flow suggests inefficiencies in converting revenue into cash, which may constrain Opko's operational flexibility and ability to fund future initiatives.

Opko Health Business Overview & Revenue Model

Company Description

Opko Health, Inc. is a diversified healthcare company focused on developing and commercializing innovative health solutions. The company operates primarily in the pharmaceuticals and diagnostics sectors, offering a range of products including proprietary pharmaceuticals, diagnostic products, and novel drug delivery systems. Opko Health is known for its commitment to advancing medical technology and improving patient outcomes through its core products such as the 4Kscore Test, a diagnostic test for prostate cancer, and a portfolio of pharmaceutical products that address various medical needs.

How the Company Makes Money

Opko Health generates revenue through multiple streams, primarily from the sale of pharmaceuticals and diagnostic tests. The company markets its proprietary drugs and therapies, including treatments for endocrinology and urology. Additionally, Opko's 4Kscore Test contributes significantly to its revenue, being a leading diagnostic tool for prostate cancer detection. The company also engages in partnerships and collaborations with other healthcare organizations, which can result in shared revenue from co-developed products or licensing agreements. Furthermore, Opko has a focus on research and development, which may lead to new product offerings and additional revenue streams in the future.

Opko Health Financial Statement Overview

Summary

Opko Health is facing substantial financial difficulties, with declining revenues, negative profitability, and cash flow challenges. Despite moderate leverage, negative returns and cash flow inefficiencies pose significant risks.

Income Statement

Opko Health's income statement reveals a challenging financial environment. The company has experienced declining revenue over the past few years, with a TTM revenue growth rate of -3.31%. Profitability metrics are concerning, with a negative net profit margin of -26.68% and an EBIT margin of -5.29% in the TTM period. The gross profit margin has decreased to 32.65% from 43.61% in the previous year. These figures indicate significant pressure on the company's profitability and operational efficiency.

Balance Sheet

The balance sheet of Opko Health shows moderate leverage with a debt-to-equity ratio of 0.31 in the TTM period, which is an improvement from previous years. However, the return on equity remains negative at -13.18%, indicating that the company is not generating positive returns for its shareholders. The equity ratio stands at a reasonable level, suggesting a stable capital structure despite the ongoing losses.

Cash Flow

Opko Health's cash flow statement highlights significant challenges. The company has negative operating cash flow and free cash flow in the TTM period, with a free cash flow growth rate of -18.22%. The operating cash flow to net income ratio is -1.40, reflecting inefficiencies in converting income into cash. Although the free cash flow to net income ratio is positive at 1.08, it is primarily due to the negative net income, indicating cash flow issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	642.07M	713.14M	863.50M	1.00B	1.77B	1.44B
Gross Profit	247.95M	311.03M	318.13M	288.20M	672.55M	541.00M
EBITDA	45.12M	135.28M	-65.52M	-270.81M	83.57M	139.09M
Net Income	-140.80M	-53.22M	-188.86M	-328.40M	-30.14M	30.59M
Balance Sheet
Total Assets	2.00B	2.20B	2.01B	2.17B	2.40B	2.47B
Cash, Cash Equivalents and Short-Term Investments	415.20M	431.94M	95.88M	153.20M	134.70M	72.20M
Total Debt	388.09M	504.44M	326.56M	305.55M	187.90M	294.57M
Total Liabilities	520.70M	834.76M	622.48M	605.70M	714.60M	801.50M
Stockholders Equity	1.31B	1.37B	1.39B	1.56B	1.69B	1.67B
Cash Flow
Free Cash Flow	-212.06M	-208.50M	-44.47M	-119.77M	6.18M	5.79M
Operating Cash Flow	-197.03M	-183.49M	-28.20M	-95.19M	38.34M	39.48M
Investing Cash Flow	348.33M	352.21M	-18.20M	91.04M	35.95M	-18.33M
Financing Cash Flow	-140.19M	184.17M	-11.30M	22.97M	-10.35M	-35.08M

Opko Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.53
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OPK, the sentiment is Negative. The current price of 1.53 is above the 20-day moving average (MA) of 1.43, above the 50-day MA of 1.45, and above the 200-day MA of 1.46, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 35.55 is Neutral, neither overbought nor oversold. The STOCH value of 34.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OPK.

Opko Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	77 Outperform	$858.93M	14.07	24.11%	―	14.46%	―
CSTL	62 Neutral	$1.01B	―	-2.69%	―	10.15%	-295.52%
FLGT	60 Neutral	$806.85M	―	-3.80%	―	13.60%	74.64%
NEO	53 Neutral	$1.35B	―	-12.99%	―	10.10%	-44.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYGN	51 Neutral	$609.62M	―	-72.52%	―	0.21%	-233.51%
OPK	50 Neutral	$1.07B	-5.64	-13.32%	―	-9.75%	-31.28%

Opko Health Corporate Events

OPKO Health Reports Q3 2025 Earnings and Strategic Moves

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company focused on establishing industry-leading positions in rapidly growing markets through its innovative technologies and expertise in discovery, development, and commercialization.

Opko Health Sells BioReference Assets to Labcorp

On September 15, 2025, OPKO Health, Inc. completed the sale of certain assets of its subsidiary, BioReference Health, to Laboratory Corporation of America Holdings (Labcorp) for up to $225 million. This transaction, which includes BioReference’s oncology and clinical testing services, marks a strategic shift for OPKO, allowing it to focus on core clinical testing operations and the growth of its 4Kscore Test franchise, while Labcorp expands its oncology services portfolio.

The most recent analyst rating on (OPK) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Opko Health stock, see the OPK Stock Forecast page.

OPKO Health’s Earnings Call: Strategic Moves Amid Challenges

During OPKO Health’s recent earnings call, the sentiment was a mix of optimism and caution. The company announced strategic initiatives like the sale of its oncology business and FDA approval for the 4Kscore test, which are expected to bolster future profitability. However, these positive developments were overshadowed by challenges such as declining revenues in the Diagnostics segment and increased operating losses in the Pharmaceutical segment, compounded by slower-than-expected product adoption.

OPKO Health Reports Q2 2025 Financial Results and Developments

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company that leverages its expertise in discovery, development, and commercialization to establish leading positions in rapidly growing markets using novel and proprietary technologies.